Achillion Pharmaceuticals Inc ACHN:NASDAQ (Common Stock)

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
10.73 0.97   9.94% 4,8004.9M
Market data is delayed by at least 20 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Previous close 10/8/2014

Latest News Headlines for Achillion Pharmaceuticals Inc

Achillion to Present Updated Clinical HCV Data on ACH-3102 and Preclinical Profile of ACH-3422 at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Achillion to Present Updated Clinical HCV Data on ACH-3102 and Preclinical Profile of ACH-3422 at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting - Late breaker poster presentation will feature updated SVR results from the Phase 2 trial of ACH-3102, NS5A inhibitor, plus sofosbuvir for the eight-week treatment of genotype 1 HCV -

Critical Alerts For Achillion Pharmaceuticals, Dreamworks Animation, SunEdison, El Pollo Loco and Whole Foods Market Released By InvestorsObserver

CHICAGO, Sept. 30, 2014 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACHN, DWA, SUNE, LOCO and WFM. To see what our analysts have discovered about a particular stock, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. (Note: You may have to copy this link into your browser then press the [ENTER] key.)

View more recent headlines

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company is engaged in the development of antivirals for the treatment of chronic hepatitis C infection (HCV), and the development of antibacterials for the treatment of resistant bacterial infections. The Company focuses on the development of four drug candidates for the treatment of HCV: ACH-1625, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase IIa clinical trial, ACH-2684, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial; ACH-2928, a NS5A inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial, and ACH-3102, a NS5A inhibitor for the treatment of HCV, which is being prepared for investigational new drug (IND), filing and initiation of a phase I clinical trial.

http://www.achillion.com

Loading...

collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open9.76
Previous Close10.73
Day High--
Day Low--
52 Week High9/4/2014 | 13.80
52 Week Low10/31/2013 | 2.26
% Off 52 Week High-22.25%
% Off 52 Week Low374.78%
Beta (5 Yr)2.34
Volatility Avg10/8/2014 | 118.35
10-Day Avg. Volume4,873,286
Market data is delayed by at least 20 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)6/30/2014 | -0.61
P/E Ratio6/30/2014 | --
Market CapSmall Cap | 1B
Shares Outstanding97.79M
Float97.5M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Ex-Date--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short17.76M
Short Ratio1.8
Short % of Float18.20%
As of 9/15/2014

Peers Information HelpACHN Achillion Pharmaceuticals Inc vs. Peers

Peers 
ACHN
Achillion Pharmaceuticals Inc
223.29%
Pfizer Inc.
-4.08%
Johnson & Johnson
14.54%
Merck & Co., Inc.
20.24%
Abbott Laboratories
9.94%
ACHN
Achillion Pharmaceuticals Inc
0.00%
Pfizer Inc.
3.54%
Johnson & Johnson
2.67%
Merck & Co., Inc.
2.92%
Abbott Laboratories
2.09%
ACHN
Achillion Pharmaceuticals Inc
9.94%
Pfizer Inc.
2.05%
Johnson & Johnson
2.46%
Merck & Co., Inc.
2.94%
Abbott Laboratories
1.64%
Compare these stocks